Rupture of an unscarred uterus in a woman with long-term steroid treatment for systemic lupus erythematosus

Case report OA: green CC0 ⤵ 1 in-corpus citation
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-08-07 ⓘ

This case describes a 36-year-old woman with long-term steroid-treated SLE who experienced spontaneous rupture of an unscarred uterus at 23 weeks gestation.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Unscarred uterine rupture in association with systemic lupus erythematosus (SLE) and long-term steroid treatment is rare. CASE: A 36-year-old primigravid woman conceived a twin gestation after in vitro fertilization therapy. At 23 weeks of gestation, she was found to have a spontaneous rupture of the uterus. Her medical history was significant for SLE for a duration of 19 years, and her condition had been maintained with prednisolone. She had no history of uterine scarring or other known risk factors for uterine rupture. The uterine fundus was the main location of the rupture and a subtotal hysterectomy was performed. CONCLUSION: Long-term treatment with systemic steroids and SLE may increase the risk of spontaneous rupture of an unscarred uterus.

My notes (saved in your browser only)

MeSH descriptors

Glucocorticoids Prednisolone Uterine Rupture Adult Cesarean Section Female Glucocorticoids Humans Lupus Erythematosus, Systemic Lupus Erythematosus, Systemic Prednisolone Pregnancy Pregnancy Trimester, Second Pregnancy, Twin Time Factors Uterine Rupture Uterine Rupture

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (9)

Source provenance

openalex
last seen: 2026-05-11T04:50:55.218851+00:00
pubmed
last seen: 2026-10-08T21:12:19.954899+00:00
License: CC0 · commercial use OK